Elosulfase alfa

INDICATION: mucopolysaccharidosis type IVA (Morquio A syndrome) — the label's pivotal trial is described in section 6.1 as 'A 24-week, randomized, double-blind, placebo-controlled clinical trial of VIMIZIM was conducted in 176 patients with MPS IVA, ages 5 to 57 years old.' The full section 1 INDICATIONS text was not in this bundle. DOSE VERBATIM (section 2.2): 'The recommended dosage of VIMIZIM is 2 mg/kg administered intravenously over a minimum range of 3.5 to 4.5 hours (based on infusion volume) once every week.' NO MILLIGRAM CEILING EXISTS: the only 'Maximum' wording anywhere in this label is a RATE ('Maximum Infusion Rate'), not a dose ceiling, so maxDose is left empty by design and the rate limits are carried in the route field and here instead. Never enter a rate as a dose ceiling. INFUSION RATE ESCALATION (Table 1, verbatim figures) — patients under 25 kg: initial rate 3 mL/hour for the first 15 minutes, then 6 mL/hour for the next 15 minutes, then increments of 6 mL/hour every 15 minutes if tolerated, up to a maximum of 36 mL/hour. Patients 25 kg or more: initial 6 mL/hour for the first 15 minutes, then 12 mL/hour for the next 15 minutes, then increments of 12 mL/hour every 15 minutes if tolerated, up to a maximum of 72 mL/hour. PREPARATION (2.4): determine the number of vials from the patient's ACTUAL body weight; withdraw and discard a volume of 0.9% sodium chloride from the 100 mL or 250 mL bag equal to the volume of VIMIZIM to be added; gently rotate to mix and avoid vigorous shaking or agitation; discard the unused portion in the vial(s). The diluted solution may contain translucent proteinaceous fibres which the in-line filter removes; discard if opaque particles are present or the solution is discoloured. STORAGE OF THE DILUTED SOLUTION (2.6): refrigerated 2 to 8 C for up to 24 hours or at room temperature 23 to 27 C for up to 24 hours; 'Diluted VIMIZIM solution must be used within 48 hours, inclusive of total infusion time. Discard if not used within 48 hours. Do not freeze or shake.' SUPERVISION AND PRE-MEDICATION (2.1): 'Administration of VIMIZIM should be supervised by a healthcare provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis.' 'Initiate VIMIZIM in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation.' 'Consider pre-medicating with antihistamines, with or without antipyretics, 30 to 60 minutes prior to the start of the infusion.' HYPERSENSITIVITY DURING INFUSION (2.3, verbatim): 'In the event of a severe hypersensitivity reaction (e.g., anaphylaxis), discontinue the VIMIZIM infusion and immediately initiate appropriate medical treatment, including use of epinephrine. In the event of a mild to moderate hypersensitivity reaction, consider slowing or temporarily interrupting the infusion, or administering additional antihistamines, antipyretics, and/or corticosteroids.'

THIS IS A PER-DOSE FIGURE, NOT A DAILY TOTAL — 2 mg/kg is given once a week, and it is the SAME dose as in adults; section 2.2 states one recommended dosage for all ages: 'The recommended dosage of VIMIZIM is 2 mg/kg administered intravenously over a minimum range of 3.5 to 4.5 hours (based on infusion volume) once every week.' AGE LIMITS (section 8.4, verbatim): 'Safety and effectiveness of VIMIZIM have been established in pediatric patients 5 years of age and older... Clinical trials with VIMIZIM were conducted in 176 patients (median age 12 years, range 5 to 57 years old) with the majority of patients in the pediatric age group (53% aged 5 to 11 years, 27% aged 12 to 17 years). Safety and effectiveness in pediatric patients below 5 years of age have not been established.' CONCENTRATION: 1 mg/mL is the UNDILUTED vial (section 3, verbatim: 'Injection: 5 mg/5 mL (1 mg/mL) as a clear to slightly opalescent and colorless to pale yellow solution in a single-dose vial'), so any volume the calculator produces is the volume of CONCENTRATE to withdraw from the vials — it is not the volume infused. That concentrate must then be added to a 100 mL bag (patient under 25 kg) or a 250 mL bag (25 kg or more) of 0.9% sodium chloride, having first removed an equal volume from the bag. Dose is calculated on ACTUAL body weight (section 2.4). NO MILLIGRAM CEILING is stated anywhere in this label, so no cap is applied; the only 'Maximum' figures are infusion RATES and they are carried in the route field, never as a dose ceiling. Verify any under-18 use against a children's formulary and against the UK SPC — this is US labelling and no UK SPC was in this bundle.